Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial

Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial

Abstract Background COVID-19 is a multisystem disease that presents acute and persistent symptoms, the postacute sequelae (PASC). Long-term symptoms may be due to consequences from organ or tissue injury caused by SARS-CoV-2, associated clotting or inflammatory processes during acute COVID-19. Vario...

Full description

Bibliographic Details
Main Authors: Carmen Lúcia Kuniyoshi Rebelatto, Alexandra Cristina Senegaglia, Claudio Luciano Franck, Debora Regina Daga, Patrícia Shigunov, Marco Augusto Stimamiglio, Daniela Boscaro Marsaro, Bruna Schaidt, Andressa Micosky, Ana Paula de Azambuja, Cleverson Alex Leitão, Ricardo Rasmussen Petterle, Valderez Ravaglio Jamur, Isadora May Vaz, Antônio Paulo Mallmann, Hipólito Carraro Junior, Eduardo Ditzel, Paulo Roberto Slud Brofman, Alejandro Correa
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Stem Cell Research & Therapy
Subjects:
COVID-19
Mesenchymal stromal cells
Postacute sequelae
Cell therapy
Online Access:https://doi.org/10.1186/s13287-022-02796-1

Internet

https://doi.org/10.1186/s13287-022-02796-1

Similar Items